The British-American biotech company Acambis reports the successful conclusion of Phase I trials of the universal flu vaccine in humans.

This vaccine is intended to provide protection against all “A” strains of the virus that causes human influenza, including pandemic strains. About two thirds of seasonal epidemics are due to these strains, as are almost all pandemic influenza strains.

This vaccine could eventually replace annual vaccinations against “A” strains.